Clinical Trials Directory

Trials / Completed

CompletedNCT04379713

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
1,511 (actual)
Sponsor
Pfizer · Industry
Sex
All
Age
42 Days – 98 Days
Healthy volunteers
Accepted

Summary

This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.

Conditions

Interventions

TypeNameDescription
BIOLOGICAL20-valent pneumococcal conjugate vaccinePneumococcal conjugate vaccine
BIOLOGICAL13-valent pneumococcal conjugate vaccinePneumococcal conjugate vaccine

Timeline

Start date
2020-05-21
Primary completion
2022-08-31
Completion
2022-08-31
First posted
2020-05-07
Last updated
2023-06-13
Results posted
2023-06-13

Locations

97 sites across 11 countries: United States, Argentina, Canada, Chile, Czechia, Finland, Germany, Greece, Hungary, Puerto Rico, Spain

Regulatory

Source: ClinicalTrials.gov record NCT04379713. Inclusion in this directory is not an endorsement.